| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
17,291 |
13,486 |
$1.56M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
18,342 |
15,290 |
$1.25M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
12,296 |
7,697 |
$645K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
5,294 |
2,871 |
$323K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
45,503 |
33,129 |
$267K |
| J1756 |
Injection, iron sucrose, 1 mg |
3,300 |
1,954 |
$182K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,929 |
3,177 |
$65K |
| J9271 |
Injection, pembrolizumab, 1 mg |
15 |
12 |
$45K |
| J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
815 |
463 |
$45K |
| 96367 |
|
2,169 |
1,198 |
$29K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
194 |
178 |
$23K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,163 |
1,181 |
$22K |
| Q5107 |
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
84 |
41 |
$19K |
| 99215 |
Prolong outpt/office vis |
399 |
309 |
$19K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
589 |
482 |
$14K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
107 |
92 |
$12K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
241 |
69 |
$8K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
222 |
205 |
$6K |
| 80053 |
Comprehensive metabolic panel |
565 |
475 |
$6K |
| 36415 |
Collection of venous blood by venipuncture |
1,868 |
1,398 |
$5K |
| J1437 |
Injection, ferric derisomaltose, 10 mg |
13 |
12 |
$4K |
| 96417 |
|
261 |
134 |
$4K |
| 99223 |
Prolong inpt eval add15 m |
133 |
96 |
$4K |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
61 |
33 |
$3K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
1,052 |
513 |
$2K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
30 |
27 |
$2K |
| J3490 |
Unclassified drugs |
119 |
52 |
$2K |
| 82728 |
|
144 |
138 |
$2K |
| J0897 |
Injection, denosumab, 1 mg |
93 |
62 |
$1K |
| 83550 |
|
131 |
125 |
$924.71 |
| 83540 |
|
132 |
126 |
$690.99 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,198 |
605 |
$495.31 |
| J0185 |
Injection, aprepitant, 1 mg |
101 |
60 |
$343.44 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
24 |
12 |
$267.90 |
| 83615 |
|
43 |
40 |
$254.56 |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
666 |
349 |
$206.10 |
| J1626 |
Injection, granisetron hydrochloride, 100 mcg |
48 |
25 |
$164.23 |
| 99233 |
Prolong inpt eval add15 m |
17 |
13 |
$129.25 |
| J3489 |
Injection, zoledronic acid, 1 mg |
32 |
16 |
$0.00 |
| 96402 |
|
17 |
12 |
$0.00 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
38 |
14 |
$0.00 |
| J1453 |
Injection, fosaprepitant, 1 mg |
59 |
37 |
$0.00 |
| J2505 |
Injection, pegfilgrastim, 6 mg |
50 |
25 |
$0.00 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
44 |
16 |
$-6.17 |
| J9045 |
Injection, carboplatin, 50 mg |
21 |
14 |
$-65.03 |
| 96415 |
|
81 |
50 |
$-74.77 |
| 96377 |
|
19 |
12 |
$-95.98 |